(PDF) P2.04-17 Pre-Therapy Radiomic Features Can

P2.04-17 Pre-Therapy Radiomic Features Can Distinguish Hyperprogression From Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1241

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Automated Image Analysis of NSCLC Biopsies to Predict Response to Anti-Pd-L1 Therapy

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Value in Health

Occupational Health

English

Understanding the Role of PD-L1/PD1 Pathway Blockade and Autophagy in Cancer Therapy

OncoTargets and Therapy

English

Continuous Targeted Kinase Inhibitors Treatment Induces Upregulation of PD-L1 in Resistant NSCLC

Scientific Reports

Multidisciplinary

English

P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population

Journal of Thoracic Oncology

Respiratory Medicine

English

Ability of 18f-FDG PET/CT Radiomic Features to Distinguish Breast Carcinoma From Breast Lymphoma

Contrast Media and Molecular Imaging

Nuclear Medicine

English

MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples

Journal of Thoracic Oncology

Respiratory Medicine

English

PD-L1 and CD8+PD1+lymphocytes Exist as Targets in the Pediatric Tumor Microenvironment for Immunomodulatory Therapy

English